Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1091041
Max Phase: Preclinical
Molecular Formula: C15H9BrN2O2
Molecular Weight: 329.15
Molecule Type: Small molecule
Associated Items:
ID: ALA1091041
Max Phase: Preclinical
Molecular Formula: C15H9BrN2O2
Molecular Weight: 329.15
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C1OC(c2cccc(Br)c2)=N/C1=C\c1cccnc1
Standard InChI: InChI=1S/C15H9BrN2O2/c16-12-5-1-4-11(8-12)14-18-13(15(19)20-14)7-10-3-2-6-17-9-10/h1-9H/b13-7-
Standard InChI Key: UBEOAFQCFKQVDY-QPEQYQDCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 329.15 | Molecular Weight (Monoisotopic): 327.9847 | AlogP: 3.19 | #Rotatable Bonds: 2 |
Polar Surface Area: 51.55 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 4.68 | CX LogP: 3.39 | CX LogD: 3.39 |
Aromatic Rings: 2 | Heavy Atoms: 20 | QED Weighted: 0.63 | Np Likeness Score: -1.54 |
1. Okamoto M, Takayama K, Shimizu T, Muroya A, Furuya T.. (2010) Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening., 18 (7): [PMID:20206532] [10.1016/j.bmc.2010.02.018] |
Source(1):